WallStSmart
BSX

Boston Scientific Corp

NYSE: BSX · HEALTHCARE · MEDICAL DEVICES

$57.61
+0.80% today

Updated 2026-04-29

Market cap
$85.62B
P/E ratio
24.10
P/S ratio
4.15x
EPS (TTM)
$2.39
Dividend yield
—
52W range
$56 – $110
Volume
15.7M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Boston Scientific Corp (BSX) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$57.61
Consensus
$104.48
+81.36%
2030 Target
$263.84
+357.98%
DCF
$46.04
-25.13% MoS
21 analysts:
12 Buy0 Hold0 Sell

Management guidance

No specific CEO revenue targets found in provided data. Most recent guidance embedded in analyst consensus: FY2026 revenue of $22.49B (12.0% growth), FY2027 revenue of $24.83B (10.4% growth). Company has not publicly issued guidance beyond 2027.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$439.74
$32.2B Rev × 20x P/S
Base case (2030)
$263.84
$32.2B Rev × 12x P/S
Bear case (2030)
$175.90
$32.2B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$14.2B$16.7B$20.1B$22.5B$24.8B$27.3B$29.8B$32.2B
Revenue growth—17.6%19.9%12.0%10.4%9.9%8.9%8.3%
EPS$2.05$2.51$3.05$3.50$3.96$4.48$4.92$5.35
P/S ratio———12.0x12.0x12.0x12.0x12.0x
Implied price———$182.18$201.02$226.15$245.00$263.84

Catalysts & risks

Growth catalysts
+ CHAMPION-AF trial success for WATCHMAN FLX device (met all primary/secondary endpoints)
+ HI-PEITHO trial showing EKOS Endovascular System superiority for acute pulmonary embolism
+ Farapulse label expansion in Europe (approved March 2026)
+ Electrophysiology segment recovery post-2026 weakness
+ Continued M&A and strategic acquisitions driving portfolio expansion
Key risks
- U.S. Electrophysiology segment facing competitive headwinds and market share loss (core growth driver under pressure)
- Multiple class action lawsuits alleging misrepresentation of EP growth sustainability and revenue guidance (July 2025-Feb 2026 period)
- Recent stock decline of 34%+ YTD and 42% from 52-week high indicates significant investor loss of confidence
- Q4 2025 results disappointed expectations; near-term growth deceleration acknowledged
- Valuation concern: Current P/E of 32x significantly above forward P/E of 16x suggests market pricing in major slowdown

Methodology

Boston Scientific Corp's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 21 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 6, 2026.